The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

This AJMC^® Webcast recap summarizes the discussion between stakeholders about the complexities of multiple myeloma disease management as well as factors that affect medication dispensing.

Download PDF

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Innovative Sub-Q Method Could Transform MM Care: Xavier Leleu, MD, PhD

ByXavier Leleu, MD, PhD,Maggie L. Shaw

August 26th 2026

Swarup Kumar, MD | Image Credit: © UConn Health

Iberdomide Complements CAR T in Myeloma: Swarup Kimar, MD

BySwarup Kumar, MD,Maggie L. Shaw

August 20th 2026

Prerna Mewawalla, MD | Image Credit: © Allegheny Health Network

Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD

ByPrerna Mewawalla, MD,Maggie L. Shaw

August 13th 2026

FDA approval | Image Credit: © jittawit21-stock.adobe.com

FDA Approves Novel Iberdomide Regimen in RRMM

ByMaggie L. Shaw

August 13th 2026

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

Related Content

Innovative Sub-Q Method Could Transform MM Care: Xavier Leleu, MD, PhD

Iberdomide Complements CAR T in Myeloma: Swarup Kimar, MD

Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD

FDA Approves Novel Iberdomide Regimen in RRMM

Predicting GLP-1 Discontinuation From Pharmacy Claims

Trending on AJMC

DOJ Abandons Olmstead Defense as Texas v Kennedy Advances

FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes

Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis

FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera

Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk